Navigation Links
Kendle Executive Dennis Hurley, DrSc to Present Keynote Address at DIA Latin American Congress 2007

Presentation to Encourage Careers in Clinical Development, Highlight Professional Development Opportunities Throughout Latin American Region

CINCINNATI, Sept. 27 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced that Vice President, Global Clinical Development - Latin America, Dennis Hurley, DrSc will give the keynote address at the DIA 4th Latin American Congress of Clinical Research on Friday, Sept. 28 at 9 a.m. The presentation, titled "Professional Development and Latin America Development," will encourage young professionals and students to pursue careers in the expanding field of clinical research. Additional Kendle participants in the presentation include Alcione Braga, RPh, Director, Global Clinical Development -- Latin America, Brazil; Maria Hurley, MBA, HR Manager, Latin America; and Daniel Mazzolenis, MD, MBA, Project Leader, Argentina.

(Logo: )

"Careers in clinical research are incredibly fulfilling," says Dr. Hurley. "Beyond the financial benefits, professionals in our industry are quite passionate and take great pride in conducting research to develop life-saving and enhancing drugs that relieve human suffering. Anyone considering a career in this rewarding and rapidly growing field can be assured that there is high demand for skilled professionals, and that there is an abundance of opportunities to develop the skills needed to succeed."

Dr. Hurley's presentation will demonstrate how the clinical development field meets three key criteria for a rewarding career and also will highlight the many programs available throughout Latin America where students and professionals alike can acquire the marketable skills needed to advance in the industry.

The presentation will be available on in the "Industry Events" section following the completion of the program.

Kendle in Latin America

Kendle provides full-service drug development programs for clinical trials in Latin America, With a base of operations in Mexico and offices in Argentina, Brazil, Chile, Colombia and Peru, six countries representing more than 80 percent of the region's population, Kendle offers an industry-leading footprint in Latin America.

In addition to ensuring the orderly, GCP-compliant conduct of clinical trials activities in this region of the world, Kendle's Latin America staff posses the in-depth experience required to conduct local clinical trial materials management and distribution as well as provide regulatory and safety services in-house. Having these services in house ensures greater control and accuracy throughout the process.

The advantages of conducting clinical trials in Latin America include:

- Solid regulatory framework with predictable timelines and reliable

processes in line with international GCP guidelines

- Access to nearly 200 million pediatric patients

- High quality data as confirmed by FDA and sponsor audits

- Hispanic and African descent populations, which are often

under-represented in clinical studies

- Expedited enrollment, with average enrollment of three to five times

faster than in traditional regions

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations and is the fourth-largest provider of Phase II-IV clinical development services worldwide. We deliver innovative and robust clinical development solutions -- from first-in-human studies through market launch and surveillance -- to help the world's biopharmaceutical companies maximize product life cycles and grow market share.

Our global clinical development business is focused on five regions -- North America, Europe, Asia/Pacific, Latin America and Africa -- to meet customer needs. With the expertise of our more than 3,000 associates worldwide, Kendle has conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at

Forward-Looking Statements

This release contains information about management's view of Kendle's future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, those set forth in the "Risk Factors" section of the Company's latest Form 10-K and other filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point, the Company specifically disclaims any obligation to do so other than as required by federal securities laws. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Where Burnt Out Executives De-stress in Natures Lap
2. Asian Business Executives Urged to Be Eco-friendly
3. BMA Welcomes Scottish Executives Move to Raise the Purchase Age of Cigarettes
4. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
5. Researchers Present Ways To Reduce The Risk Of Dementia
6. Researchers Present Data Regarding The Efficiency Of Herbs
7. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
8. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
9. Drug Reactions First Present Themselves In The Mouth
10. Reminiscing Into The Past Makes You Dissatisfied With The Present
11. Living In The Past Indicates Dissatisfaction With Present
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... An inventor, from Hopkinsville, Ky., thought there ... home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. provides ... so, it could help to prevent potential overdose situations. As a result, it ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television ... an interesting show that delves into an array of issues that are presently affecting ... benefit from open dialogue, this show is changing the subjects consumers focus on, one ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ... acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the ... company UCB S.A. (Euronext: UCB). ... KU from UCB for total consideration of approximately ... customary working capital adjustment, a deduction of certain ...
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... Un nuevo enfoque combina la ... cáncer avanzado.   --> Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... --> Clinical Cancer Research . --> ...
Breaking Medicine Technology: